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Background
Africa is a crucial setting for preventive HIV clinical trials.
We present our experience of setting up a collaborative
network of African clinical research centers (CRC).
Methods
IAVI supports nine CRCs in Africa: Kilifi and Nairobi,
Kenya; Masaka and Entebbe, Uganda; Kigali, Rwanda;
Lusaka and Ndola, Zambia; and Cape Town and Rusten-
burg, South Africa. The aim of the network is to support
capacity and research on HIV epidemiology and immu-
nology relevant for HIV preventive clinical trials, and to
conduct these trials from phase 1 to efficacy. All CRCs pro-
vide VCT, and at-risk volunteers are offered enrollment
into prospective HIV epidemiology and incidence studies.
The populations vary by CRC and include HIV-discordant
couples, commercial sex workers, and men who have sex
with men. Volunteers who become HIV infected are
enrolled into an early HIV infection study. Lower-risk,
HIV-uninfected volunteers may be referred to phase I and/
or II vaccine trials. Laboratory facilities at each CRC partic-
ipate in external, independent quality assurance programs
to ensure standardization and comparability of data
across CRCs.
Results
Since its inception in 2001, this network has provided
VCT for over 105,000 individuals, over 19,000 (18%) of
whom have enrolled into research studies. This includes
eight phase I & II HIV vaccine clinical trials in Kenya, Zam-
bia, Rwanda, Uganda and South Africa. Locally-appropri-
ate laboratory reference intervals have been established
across the network. The HIV incidence among higher-risk
volunteers varies by CRC, from 2.8–7.7 cases/100 PY with
over 10,000 PY accumulated. 420 incident infections have
been diagnosed and are being followed up.
Conclusion
Network CRCs have conducted phase I & II trials accord-
ing to GCP and/or large-scale epidemiology studies
involving thousands of volunteers. The network has pro-
vided opportunities for multicenter clinical trials and
access to populations with variable risk for HIV under
standardized data, laboratory, and clinical operations.
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